Musings on genome medicine: cholesterol and coronary artery disease by Nathan, David G & Orkin, Stuart H
Genome Medicine 2009, 1 1: :60
Musings
M Mu us si in ng gs s   o on n   g ge en no om me e   m me ed di ic ci in ne e: :   c ch ho ol le es st te er ro ol l   a an nd d   c co or ro on na ar ry y   a ar rt te er ry y   d di is se ea as se e
David G Nathan and Stuart H Orkin
Address: Dana-Farber Cancer Institute, Binney Street, Boston, MA 02115, USA.
Correspondence: David G Nathan. Email: david_nathan@dfci.harvard.edu
A Ab bs st tr ra ac ct t
Cholesterol levels and not inflammatory markers are the major variables that pose a risk of
coronary artery disease. Diabetes greatly increases the risk at any cholesterol level. Coronary
artery disease and cancer are linked by a common protein - an apoptotic protein that also
functions as a regulator of insulin secretion.
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Although it is difficult for a pair of hematologists/oncolo-
gists to admit, cardiologists teamed with public health
aficionados and pharmaceutical companies have made a
huge dent in the death and disability rates induced by
atherosclerosis and coronary artery disease (CAD). The
relatively puny successes of our brethren in oncology pale by
comparison (although we have definitely turned the corner).
In this month’s Musings, we address the role of cholesterol
in CAD.
Much of the success in atherosclerosis and CAD has derived
from changes in life style that have been informed by
increasing awareness of the risks of saturated fat and
cholesterol in the diet and a better understanding of the
hazards of diabetes, obesity, hypertension and smoking.
Here emerge interesting similarities (and differences) between
CAD and cancer. Cancer incidence is only slightly influenced
by diet and not all by hypertension, but obesity influences
cancer incidence and over 30% of cancer incidence is due to
tobacco use. Curiously, diabetes and cancer are unexpectedly
linked, as we discuss below. Furthermore, hypertensive
heart disease, CAD and cancer are particularly dangerous
illnesses in African Americans, which strongly supports a
genetic basis for both diseases.
Although the role of cholesterol in the genesis of athero-
sclerosis and CAD seems obvious today, the pathway to that
recognition has been littered with obstacles. Confusion
about the primary (and indeed uniquely essential) role of
plasma cholesterol levels in the genesis of CAD stems from
misinterpretation of the results of the Framingham Heart
Study. The overlap of cholesterol levels in individuals who
did or did not have CAD prompted William Castelli, an
experienced observer, to state: ‘cholesterol levels by them-
selves reveal little about a patient’s coronary artery disease
risk’ [1]. Although Castelli recognized that almost every
individual with a blood cholesterol level greater than 300 mg
per deciliter did have CAD, he failed to note that no
individual in the Framingham cohort with a cholesterol level
lower than 140 mg per deciliter developed CAD.
Clearly, the problem we face is quite simple; we accept
cholesterol levels that induce a high risk of CAD as ‘normal’.
In fact, if one plots CAD risk as a function of cholesterol
level, a near-linear relationship emerges [2,3]: the lower the
cholesterol level and the longer the low level is maintained,
the lower the risk. It is frustrating to read accounts in major
journals that other factors, for example vague indices of
inflammation such as C-reactive protein [4-6], might have
any important primary role in the pathogenesis of heart
disease. It is certainly true, as demonstrated years ago by
Ross and Agius [7], that invasion of the intimal cells of
arteries by cholesterol is associated with macrophage
activation, and the release of damaging cytokines within theintima would certainly result in inflammation of the vessel
wall. Atherosclerosis, through activation of macrophages,
can actually cause ulcerating lesions in the great vessels. So
inflammation clearly has a role, but positing that it has a
primary role in the disorder is not supported by the data.
Atherosclerosis is a chronic disease that often begins in
childhood when excess plasma low density lipoprotein (LDL)
particles, consisting predominantly of cholesterol esters and
a protein called ApoB100, accumulate in plasma and spill
over into vessel walls [8,9]. Approximately 70% of choles-
terol absorbed from the diet or synthesized in the liver by 3-
hydroxyl-3-methylglutaryl coenzyme A reductase (HMGCoA
reductase, the target of statins) is carried in the circulation
on LDL particles. These circulating particles deliver lipids to
cell membranes via LDL receptors that dump the particles
into lysosomes in which the cholesterol esters are processed
and from which the free cholesterol is transferred to cell
membranes. A paucity of lipoproteins leads to cholesterol
deficiency in the cell membrane and concomitant cell defor-
mity and dysfunction, the Bassen-Kornzweig syndrome [10].
An excess of LDL production or a deficiency of lipoprotein
receptors leads to accumulation of LDL-cholesterol particles
in the circulation [8]. These excessive particles are engulfed
by ‘scavenger’ receptors, particularly on macrophages. The
macrophages turn into foam cells and release toxic cyto-
kines. The process of atherosclerosis is thus initiated.
Appallingly, CAD is readily detectable in a high proportion of
otherwise ‘healthy’ teenage American males on a high-salt,
high-fat, meat diet [11], just as rabbits fed cholesterol rapidly
develop the disease [12]. The rate and extent of athero-
sclerosis is therefore influenced by diet, and both are markedly
accelerated by inactivating mutations in LDL receptor genes
and mutations in the ApoB genes that interfere with the
binding of LDL to the LDL receptor [8]. The two mutations
are uncommon but dominant.
African Americans have a higher incidence and severity of
heart disease than Caucasian Americans, even when diabetes,
obesity and smoking are taken into account [13]. But African
Americans with inactivating mutations of PCSK9, a gene
whose product inhibits the synthesis of LDL receptors, have
much lower rates of heart disease, as defined by myocardial
infarction, sudden death or need for revascularization [14].
This recent observation provides overwhelming evidence
that LDL-cholesterol levels are the key to CAD. Evidence of
inflammation, such as increased serum levels of C-reactive
protein, are a secondary consequence of atherosclerosis and
may be of some predictive value in particular circumstances,
but these are epiphenomena and therefore relatively
unimportant. The medical focus must be on cholesterol.
The high incidence of CAD in diabetes is not entirely under-
stood, but it is certainly related, at least in part, to
cholesterol levels, and is perhaps enhanced by elevated
triglycerides. It is tempting to propose that glycosylation of
endothelial cells and/or macrophages may also have a role
and may enhance atherosclerosis at any level of LDL, but
that is purely speculative. Far less speculative is the
remarkable cell biological and biochemical link between
cancer incidence and diabetes (and thus CAD) recently
discovered by Danial, Walensky and their colleagues [15].
These investigators [15] have observed that BAD, an
apoptosis promoting protein that contributes to cancer
development when it is inactivated, has a major role in
insulin production. A chemically stabilized peptide derived
from BAD stimulates glucokinase and thus insulin
production in type 2 diabetic rodents and normalizes their
glucose tolerance curves. Here we observe a perfect example
of ‘the wisdom of the body’. The same gene is used to prevent
cancer and diabetes with its concomitant CAD, three of the
most important diseases of mankind. Furthermore, the
study demonstrates that the chemically stabilized peptide
approach may turn non-receptor proteins into drug targets.
Although enormous progress has been made in the manage-
ment of the CAD epidemic that has plagued ‘developed’
societies since the 20th century and although new avenues of
research are regularly opening, we remain troubled by a
vexing problem. If CAD does not occur below an LDL
cholesterol level of 140 mg/deciliter, why do we fail to
maintain our citizens as close to that level as reasonable by
diet if possible and with statins if not? At what age should we
begin that approach? We know that many teenagers on a
standard American diet already have the disease. Therefore,
we must start early, but how early? Children need
cholesterol for proper brain development. These are the
issues that should be front and center. We should not be
distracted by epiphenomena.
A Ab bb br re ev vi ia at ti io on ns s
CAD, coronary artery disease; HMGCoA, 3-hydroxyl-3-
methylglutaryl coenzyme A reductase; LDL, low density
lipoprotein.
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